{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:51:47Z","timestamp":1787615507035,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejps.2026.107570","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:29:48Z","timestamp":1780118988000},"page":"107570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["European science for health research needs and priorities"],"prefix":"10.1016","volume":"223","author":[{"given":"Mareike","family":"Lutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Moleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7175-1499","authenticated-orcid":false,"given":"Hubert G.M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejps.2026.107570_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251488","article-title":"Getting to the bottom of research funding: acknowledging the complexity of funding dynamics","volume":"16","author":"Aagaard","year":"2021","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.ejps.2026.107570_bib0002","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12961-025-01385-x","article-title":"Impact upfront: novel format for Novo Nordisk foundation funding","volume":"23","author":"Balling","year":"2025","journal-title":"Health Res. Policy. Syst."},{"key":"10.1016\/j.ejps.2026.107570_bib0003","series-title":"EU As a Science Innovator","author":"Barr","year":"2025"},{"issue":"2","key":"10.1016\/j.ejps.2026.107570_bib0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drudis.2017.10.007","article-title":"Medicinal chemistry in drug discovery in big pharma: past, present and future","volume":"23","author":"Campbell","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2026.107570_bib0005","unstructured":"CESAER, Coimbra Group, EUA, EU-LIFE, The Guild, LERU, and YERUN, Proposed joint amendments to the FP10 legal texts, 2025, available at: https:\/\/www.cesaer.org\/content\/10-library\/2025\/fp10-amendments\/joint-amendments-fp10-01.12.2025.pdf (accessed 15 February 2026)."},{"issue":"10","key":"10.1016\/j.ejps.2026.107570_bib0006","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s11095-017-2192-5","article-title":"Reflections on the future of pharmaceutical public-private partnerships: from input to impact","volume":"34","author":"De Vrueh","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107570_bib0007","unstructured":"DirectorateGeneral for Research and Innovation of the European Commission, Evaluation study of the European framework programmes for research and innovation for a resilient Europe: final report (Phase 1), 2023, available at: https:\/\/op.europa.eu\/en\/publication-detail\/-\/publication\/b387aa73-012e-11ee-87ec-01aa75ed71a1 (accessed 23 February 2026)."},{"key":"10.1016\/j.ejps.2026.107570_bib0008","unstructured":"DirectorateGeneral for Research and Innovation of the European Commission, European Research Area Platform, 2026, available at: https:\/\/european-research-area.ec.europa.eu\/era-act (accessed 15 February 2026)."},{"key":"10.1016\/j.ejps.2026.107570_bib0009","unstructured":"Draghi, M.. The future of european competitiveness: report to the European commission. 9 September 2024, doi:10.2872\/9356120, available at https:\/\/commission.europa.eu\/document\/download\/97e481fd-2dc3-412d-be4c-f152a8232961_en?filename=The%20future%20of%20European%20competitiveness%20_%20A%20competitiveness%20strategy%20for%20Europe.pdf (accessed 15 February 2026)."},{"key":"10.1016\/j.ejps.2026.107570_bib0010","unstructured":"European Commission, Horizon Europe Work Programme 2026\u20132027: 4. Health, 2025c, available at https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/docs\/2021-2027\/horizon\/wp-call\/2026-2027\/wp-4-health_horizon-2026-2027_en.pdf (accessed 23 February 2026)."},{"key":"10.1016\/j.ejps.2026.107570_bib0011","unstructured":"European Commission, Proposal for a regulation of the European parliament and of the council establishing horizon Europe, the framework programme for research and innovation, for the period 2028-2034 laying down its rules for participation and dissemination, and repealing regulation (EU) 2021\/695, 2025a, available at https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:52025PC0543 (accessed 15 February 2026)."},{"key":"10.1016\/j.ejps.2026.107570_bib0012","unstructured":"European Commission, Proposal for a regulation of the European parliament and of the council on establishing the European competitiveness fund ('ECF\u2019), including the specific programme for defence research and innovation activities, repealing Regulations (EU) 2021\/522, (EU) 2021\/694, (EU) 2021\/697, (EU) 2021\/783, repealing provisions of regulations (EU) 2021\/696, (EU) 2023\/588, and amending regulation (EU) [EDIP], 2025b, available at https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:52025PC0555 (accessed 15 February 2026)."},{"key":"10.1016\/j.ejps.2026.107570_bib0013","unstructured":"European Commission, Regulation (EU) 2025\/327 of the European parliament and of the council of 11 february 2025 on the European health data space and amending directive 2011\/24\/EU and regulation (EU) 2024\/2847, 2025d, available at https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=OJ:L_202500327 (accessed 23 February 2026)."},{"key":"10.1016\/j.ejps.2026.107570_bib0014","unstructured":"European Medicines Agency (EMA), 2021, available at https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/regulatory-science-research\/regulatory-science-research-needs (accessed 23 February 2026)."},{"issue":"5","key":"10.1016\/j.ejps.2026.107570_bib0015","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.xphs.2021.10.002","article-title":"Unmet medical need as a driver for pharmaceutical sciences - A survey among scientists","volume":"111","author":"Kusynov\u00e1","year":"2022","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.ejps.2026.107570_bib0016","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.xphs.2023.04.015","article-title":"Mantel-Teeuwisse AK. Pharmaceutical scientists' Perspectives on capacity building in pharmaceutical sciences","volume":"112","author":"Kusynov\u00e1","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2026.107570_bib0018","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/mpp.12380","article-title":"The influence of funding sources on the scientific method","volume":"17","author":"Okagaki","year":"2016","journal-title":"Mol. Plant Pathol."},{"issue":"Suppl. 2","key":"10.1016\/j.ejps.2026.107570_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000549149","article-title":"EndoCompass project: the place of endocrinology in European research funding - an analysis of Horizon 2020","volume":"98","author":"Pandurevi\u0107","year":"2025","journal-title":"Horm. Res. Paediatr."},{"issue":"11","key":"10.1016\/j.ejps.2026.107570_bib0021","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1873-3468.13846","article-title":"European research council: bottom-up principles of the scientific council and top-down proposal of the resigned president","volume":"594","author":"Porta","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejps.2026.107570_bib0022","series-title":"Qualtrics Survey Software","year":"2026"},{"key":"10.1016\/j.ejps.2026.107570_bib0017","unstructured":"NEED, available at https:\/\/health-needs.eu\/index.php\/en\/ (accessed from 2024 onwards during the conduct of this project)."},{"key":"10.1016\/j.ejps.2026.107570_bib0023","unstructured":"Science Business, 2026, available at https:\/\/sciencebusiness.net\/news\/r-D-funding\/european-defence-fund\/funding-radar-european-defence-fund-calls-research (accessed 23 February 2026)."},{"key":"10.1016\/j.ejps.2026.107570_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1122405","article-title":"Enabling technologies driving drug research and development","volume":"10","author":"Vass","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.ejps.2026.107570_bib0025","unstructured":"Von der Leyen U., Speech at the Annual EU Budget Conference, 2025, available at https:\/\/ec.europa.eu\/commission\/presscorner\/api\/files\/document\/print\/en\/speech_25_1284\/SPEECH_25_1284_EN.pdf (accessed 15 February 2026)."},{"issue":"1","key":"10.1016\/j.ejps.2026.107570_bib0026","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11606-021-07064-1","article-title":"Methods for identifying health research gaps, needs, and priorities: a scoping review","volume":"37","author":"Wong","year":"2022","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"10.1016\/j.ejps.2026.107570_bib0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:14:28Z","timestamp":1781752468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"alternative-id":["S0928098726001442"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107570","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European science for health research needs and priorities","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107570"}}